Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
AnemiaHemosiderosis
Interventions
DRUG

Deferasirox

Deferasirox available as 125 mg, 250 mg or 500 mg tablets

Trial Locations (28)

10021

New York Presbyterian Hospital, New York

94305

Stanford Hospital, Stanford

94609-1809

Children's Hospital and Research center at Oakland, Oakland

02115

Childres's Hospital Boston, Boston

19104-4399

Children's Hospital of Philadelphia, Philadelphia

Unknown

Novartis Investigative Site, Bruges

Novartis Investigative Site, Brussels

Novartis Investigative Site, Ghent

Novartis Investigative Site, La Louvière

Novartis Investigative Site, Leuven

Novartis Investigative Site, Montreal

Novartis Investigative Site, Toronto

Novartis Investigative Site, Créteil

Novartis Investigative Site, Le Kremlin-Bicêtre

Novartis Investigative Site, Lille

Novartis Investigative Site, Troyes

Novartis Investigative Site, Düsseldorf

Novartis Investigative Site, Hanover

Novartis Investigative Site, Ulm

Novartis Investigative Site, Bologna

Novartis Investigative Site, Brindisi

Novartis Investigative Site, Cagliari

Novartis Investigative Site, Genova

Novartis Investigative Site, Milan

Novartis Investigative Site, Pavia

Novartis Investigative Site, Rome

Novartis Investigative Site, Torino

Novartis Investigative Site, London

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY